Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer.
Company Details
- Employees
- 83
- Founded
- -
- Address
- 828 Winter St, Waltham,massachusetts 02451,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.xiliotx.com
- Keywords
- Biotechnology, Immunotherapeutics, cancer.
- HQ
- Waltham, Massachusetts
Xilio Therapeutics, Inc. Questions
Xilio Therapeutics, Inc.'s website is http://www.xiliotx.com
Xilio Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/xilio-tx
Xilio Therapeutics, Inc. has
83 employees.
View email and phone details for 83
employees at Xilio Therapeutics, Inc..
Xilio Therapeutics, Inc.'s industry is
Biotechnology Research
Xilio Therapeutics, Inc.'s top competitors are
Beam Therapeutics,
X4 Pharmaceuticals,
Kymera Therapeutics,
Abbvie,
Sarepta Therapeutics,
Kojin Therapeutics,
Vertex Pharmaceuticals,
Abcuro, Inc,
Invivyd,
Newleos Therapeutics.
Xilio Therapeutics, Inc.'s categories are Biotechnology Research
Xilio Therapeutics, Inc.'s founding year is 2016
